Psoriasis Treatment Denied by Insurance? How to Appeal

Psoriasis affects more than 7.5 million Americans, and for those with moderate-to-severe disease, biologic medications can be life-changing. Yet insurance denials for psoriasis biologics are among the most common dermatology disputes. If your insurer has refused to cover Cosentyx, Skyrizi, Humira, Tremfya, Taltz, Stelara, Ilumya, or Enbrel, you have strong grounds to appeal — and a well-documented appeal frequently succeeds.

Why Insurers Deny Psoriasis Biologics

Insurers most commonly deny psoriasis biologic therapy for these reasons:

Step therapy requirements: Most payers require failure on conventional systemic agents first — typically methotrexate, cyclosporine, or acitretin — before approving a biologic. Some also require a phototherapy trial.

Insufficient severity documentation: Insurers want to see objective measures confirming moderate-to-severe disease. If your chart doesn't include PASI, BSA, and DLQI scores, the reviewer may downgrade your severity.

Formulary preferences: Your insurer may cover one biologic but not another, requiring you to fail on their preferred agent before approving your dermatologist's choice.

"Not medically necessary" determination: Vague language that often means the documentation submitted didn't meet the payer's criteria, not that your condition doesn't require treatment.

Severity Scoring: Your Most Important Documentation

Objective scoring tools are the backbone of a successful psoriasis appeal.

PASI (Psoriasis Area and Severity Index): Scores range from 0–72. A score of 10 or higher is the standard threshold for moderate-to-severe disease. Most biologics were approved in clinical trials at PASI 12+. Document your baseline PASI before and after failed conventional therapy.

BSA (Body Surface Area): BSA involvement of 10% or greater is a standard moderate-to-severe threshold. Each hand palm equals approximately 1% BSA.

DLQI (Dermatology Life Quality Index): Scores above 10 indicate a very large effect on quality of life. The DLQI captures how psoriasis affects daily activities, work, relationships, and emotional well-being — factors that pure skin measurements miss.

Ask your dermatologist to formally document all three measures at each visit and to include them explicitly in Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization letters.

Biologic Classes and How to Frame Step Therapy Failures

Different biologic classes target different inflammatory pathways:

• TNF inhibitors: Humira (adalimumab), Enbrel (etanercept) — older class, broader insurer familiarity
• IL-12/23 inhibitor: Stelara (ustekinumab) — dosed every 12 weeks after induction
• IL-17 inhibitors: Cosentyx (secukinumab), Taltz (ixekizumab) — particularly effective for plaque and nail psoriasis
• IL-23 inhibitors: Skyrizi (risankizumab), Tremfya (guselkumab), Ilumya (tildrakizumab) — newer agents with strong PASI 90/100 response rates

If your insurer requires step therapy through a TNF inhibitor first, document the specific reason your dermatologist recommended bypassing that step — for example, contraindications like active infections, demyelinating disease, or heart failure that make TNF inhibitors inappropriate.

Phototherapy and Conventional Therapy Step Requirements

Many insurers require documentation that phototherapy was tried before approving a biologic. Key points:

• Narrow-band UVB (NB-UVB) is typically required; PUVA may satisfy the requirement as well
• Document why phototherapy was not feasible if you couldn't complete the trial (geographic access to a light therapy center, inability to attend 3x/week sessions, disease worsening during trial)
• For conventional agents: document methotrexate trial with hepatotoxicity monitoring labs, or contraindications to cyclosporine (renal impairment, hypertension), or teratogenicity concerns with acitretin in women of childbearing age

National Psoriasis Foundation Guidelines as Appeal Evidence

The National Psoriasis Foundation (NPF) and American Academy of Dermatology (AAD) publish evidence-based treatment guidelines that insurers are expected to consider. Cite them directly in your appeal:

• AAD-NPF Guidelines of Care for the Management of Psoriasis with Biologics (2019, updated)
• NPF's Medical Board position statement on step therapy and patient access
• NPF's "Step Therapy" resources for patients, which include template appeal letters

These guidelines explicitly state that patients with moderate-to-severe psoriasis who have failed conventional therapy are appropriate candidates for biologic therapy, and that arbitrary step therapy requirements that ignore clinical judgment are not evidence-based.

Writing Your Appeal

A strong psoriasis biologic appeal includes:

1. A letter of medical necessity from your dermatologist citing PASI, BSA, and DLQI scores
2. Documentation of all conventional therapy trials with dates, doses, and reason for failure
3. A phototherapy access statement if applicable
4. Reference to FDA labeling for the requested biologic
5. Citation of AAD/NPF guidelines
6. A statement of urgency if disease is causing joint involvement (psoriatic arthritis risk), psychological impairment, or inability to work

Request a peer-to-peer review between your dermatologist and the insurance medical director if the initial appeal is denied. Dermatologist-to-physician review is more successful than written appeals alone.

Fight Back With ClaimBack

ClaimBack can help you draft a complete, evidence-based psoriasis biologic appeal letter in minutes. Our platform incorporates PASI/BSA/DLQI documentation frameworks, NPF guideline citations, and step therapy rebuttal language used by successful appellants.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied